These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 21135702)
1. Surgery, Crohn's disease, and the biological era: has there been an impact? Slattery E; Keegan D; Hyland J; O'donoghue D; Mulcahy HE J Clin Gastroenterol; 2011 Sep; 45(8):691-3. PubMed ID: 21135702 [TBL] [Abstract][Full Text] [Related]
2. Trends in surgery for Crohn's disease in the era of infliximab. Jones DW; Finlayson SR Ann Surg; 2010 Aug; 252(2):307-12. PubMed ID: 20585239 [TBL] [Abstract][Full Text] [Related]
3. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Szamosi T; Banai J; Lakatos L; Czegledi Z; David G; Zsigmond F; Pandur T; Erdelyi Z; Gemela O; Papp M; Papp J; Lakatos PL Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):872-9. PubMed ID: 19648821 [TBL] [Abstract][Full Text] [Related]
4. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Ramadas AV; Gunesh S; Thomas GA; Williams GT; Hawthorne AB Gut; 2010 Sep; 59(9):1200-6. PubMed ID: 20650924 [TBL] [Abstract][Full Text] [Related]
5. A 5-year prospective observational study of the outcomes of international treatment guidelines for Crohn's disease. Cullen G; Keegan D; Mulcahy HE; O'Donoghue DP Clin Gastroenterol Hepatol; 2009 Mar; 7(3):323-8; quiz 252. PubMed ID: 19174193 [TBL] [Abstract][Full Text] [Related]
7. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease. Picco MF; Zubiaurre I; Adluni M; Cangemi JR; Shelton D Am J Gastroenterol; 2009 Nov; 104(11):2754-9. PubMed ID: 19584832 [TBL] [Abstract][Full Text] [Related]
8. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354 [TBL] [Abstract][Full Text] [Related]
9. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Kane SV; Chao J; Mulani PM Adv Ther; 2009 Oct; 26(10):936-46. PubMed ID: 19838649 [TBL] [Abstract][Full Text] [Related]
10. Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients. Pedersen N; Duricova D; Lenicek M; Elkjaer M; Bortlik M; Andersen PS; Vitek L; Davidsen B; Wewer V; Lukas M; Munkholm P Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1196-203. PubMed ID: 20739896 [TBL] [Abstract][Full Text] [Related]
11. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P; Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256 [TBL] [Abstract][Full Text] [Related]
12. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease. Taxonera C; Rodrigo L; Casellas F; Calvet X; Gómez-Camacho F; Ginard D; Castro M; Castro L; Ponce M; Martínez-Montiel P; Ricart E; Gisbert JP; López-San Román A; Morales JM; Casado MA J Clin Gastroenterol; 2009; 43(10):950-6. PubMed ID: 19448569 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of newly diagnosed Crohn's disease: a comparative, retrospective study before and after infliximab availability. Domènech E; Zabana Y; Garcia-Planella E; López San Román A; Nos P; Ginard D; Gordillo J; Martínez-Silva F; Beltrán B; Mañosa M; Cabré E; Gassull MA Aliment Pharmacol Ther; 2010 Jan; 31(2):233-9. PubMed ID: 19832727 [TBL] [Abstract][Full Text] [Related]
14. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Chen DM; Pritchard ML; Sandborn WJ Clin Gastroenterol Hepatol; 2006 May; 4(5):621-30. PubMed ID: 16678077 [TBL] [Abstract][Full Text] [Related]
15. Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies. Vermeire S; van Assche G; Rutgeerts P Aliment Pharmacol Ther; 2007 Jan; 25(1):3-12. PubMed ID: 17229216 [TBL] [Abstract][Full Text] [Related]
16. Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates? Canedo J; Lee SH; Pinto R; Murad-Regadas S; Rosen L; Wexner SD Colorectal Dis; 2011 Nov; 13(11):1294-8. PubMed ID: 20969715 [TBL] [Abstract][Full Text] [Related]
18. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania. Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373 [TBL] [Abstract][Full Text] [Related]
19. Infliximab use in luminal Crohn's disease. Richter JA; Bickston SJ Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey. Matsumoto T; Iida M; Motoya S; Haruma K; Suzuki Y; Kobayashi K; Ito H; Miyata M; Kusunoki M; Chiba T; Yamamoto S; Hibi T Dis Colon Rectum; 2008 Jun; 51(6):916-23. PubMed ID: 18322754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]